FDA label
What is Motegrity used for?
Motegrity contains prucalopride. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “MOTEGRITY® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Motegrity?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Motegrity, tablet, film coated
Indications and Usage, quoted from the label by Takeda Pharmaceuticals America, Inc. (NDA210166). Cross-references to other label sections are left out.
MOTEGRITY® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Source: DailyMed label, set id bca1e4c6-4b2b-4876-8ab3-654629c4ff1b, version 12, effective July 17, 2025. NDC 54092-546, one of 2 listings for this product.
Questions
What is Motegrity used for?
The FDA label says: “MOTEGRITY® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.”
What drug class is Motegrity?
FDA lists prucalopride in the Serotonin-4 Receptor Agonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.